Réactifs et instruments pour l'immunologie, la biologie cellulaire et la biologie moléculaire.
 
> Citral [5392-40-5]

Citral [5392-40-5]

Imprimer Imprimer
Identifiez-vous

Référence HY-N7083-100mg

Conditionnement : 100mg

Marque : MedChemExpress

Contactez votre distributeur local :


Téléphone : +1 850 650 7790

Description

Citral is an orally active monoterpene compound in lemon grass essential oil and a natural ALDH1A inhibitor, which can induce apoptosis and cycle arrest in breast cancer cell lines, and has analgesic, anti-injurious and anti-inflammatory effects[2][3].
In Vitro

Citral (10, 50, 100 μg/mL, 72 h) has no cytotoxicity to J774 macrophages[1].
Citral (0-0.5 μM, 72 h) inhibits cell proliferation and induces apoptosis and cell cycle arrest in MCF-7 breast cancer cell line[2].
Citral (0-100 μg/mL, 72 h) exhibits anti-proliferative and pro-apoptotic activities in MDA-MB-231 breast cancer cell line[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Citral Related Antibodies

Cell Viability Assay[1].

Cell Line: J774 cell
Concentration: 10, 50, 100 μg/mL
Incubation Time: 72 h
Result: Didn't affect the cell viability of J774 cells

Cell Proliferation Assay[2].

Cell Line: MCF-7 cell
Concentration: 0-0.5 μM
Incubation Time: 72 h
Result: Inhibited the proliferation of MCF-7 cells

Cell Cytotoxicity Assay[3].

Cell Line: MDA-MB-231 cell
Concentration: 0-100 μg/mL
Incubation Time: 72 h
Result: Inhibited the cell viability of MDA-MB-231 cells
In Vivo

Citral (100 mg/kg, p.o.) improves the anti-hyperalgesic and anti-inflammatory activities in pleurisy mice[1].
Citral (10, 20, 40 mg/kg, i.p.) prevents LPS induced mouse endometritis by activating the Nrf2 signaling pathway and inhibiting ferroptosis[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: pleurisy adult (2 to 3 months old) male Swiss mice[1].
Dosage: 100 mg / kg body weight
Administration: oral gavage (p.o.)
Result: Reduced white blood cell count and TNF-α expression level [1].
Animal Model: Female BALB/c mice[4].
Dosage: 10, 20, 40 mg/kg body weight
Administration: intraperitoneal injection (i.p.)
Result: Attenuated uterine pathological damage, infammation, and ferroptosis[4].
Masse moléculaire

152.23

Formule

C10H16O
CAS No.
Appearance

Liquid (Density: 0.888 g/cm3)

Color

Colorless to light yellow

SMILES

C/C(C)=C\CC/C(C)=C/C=O
Structure Classification
Initial Source
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage
Pure form -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
Solvant et solubilité
In Vitro: 

DMSO : 100 mg/mL (656.90 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 6.5690 mL 32.8450 mL 65.6901 mL
5 mM 1.3138 mL 6.5690 mL 13.1380 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (16.42 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (16.42 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Pureté et documentation
Références